Uncategorized
Ophthotech announces new Zimura clinical trials
Ophthotech will begin an open-label phase 2a clinical trial of Zimura, a complement factor C5 inhibitor for patients with wet age-related macular degeneration, according to a press release.Zimura (avacincaptad pegol) will be administered in combination with Lucentis (ranibizumab, Genentech) in patients who have not previously been treated with anti-VEGF drugs. A range of dosing regimens will be assessed, the release said.